A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH)

Prior treatment

• History of hospitalization for acute cardiovascular events within 3 months prior to the date of consent
• Contraindications for each assigned drug, as applicable

Other illness

• Type 1 diabetes
• Symptomatic heart failure (NYHA Class III or IV)
• Currently in active treatment for malignancy

Lab values

• Estimated GFR\<45 ml/min/1.73m²
• AST or ALT greater than 3 times the normal upper limit

Other

• Pregnant and nursing women
• If the investigator determines that assignment to the standard glycemic control arm raises ethical concerns

• ≥19 years of age
• Patient agreed to participate in the study and signed a written informed consent form
• Type 2 diabetes (ADA criteria)
• HbA1c≥7.0% and \<10.0% in patients receiving monotherapy, dual-combination therapy, or triple-combination therapy (when the submaximal dose was administered) with oral antidiabetic drugs (OADs)
• Any of the following:
• Patients who one or more of the following conditions
• Coronary artery disease
• Atherosclerotic ischemic stroke, transient ischemic attack, carotid artery disease, peripheral artery disease, abdominal aortic aneurysm
• Prevalence of diabetes ≥10 years
• Left ventricular hypertrophy
• Albuminuria
• Chronic kidney disease (eGFR\<60mL/min/1.73m²)
• Diabetic Retinopathy
• Diabetic neuropathy or B. Patients who have two or more of the following cardiovascular risk factors
  • (1) Family history of early-onset ASCVD (first-degree relatives with disease before age 55 for men and before age 65 for women) (2) Hypertension (on medication or with SBP≥140 mm Hg or DBP≥90 mm Hg) (3) Low HDL cholesterol concentration (\<40 mg/dL) (4) Current smoker (5) Obese (BMI≥25 kg/m²)